January 16, 2020
House Bill 2536, 86th Legislative Regular Session (2019), added new Chapter 441 to the Texas Health and Safety Code. Chapter 441, entitled Drug Cost Transparency, requires pharmaceutical drug manufacturers to annually report to the Texas Health and Human Services Commission (HHSC) current wholesale acquisition cost information for U.S. Food and Drug Administration (FDA)-approved drugs sold in or into Texas. Manufacturers are also required to separately report specific information about certain wholesale acquisition cost increases.
HHSC will implement these new reporting requirements in phases to allow pharmaceutical drug manufacturers time to gather and submit the required information. HHSC will accept wholesale acquisition cost information for FDA-approved prescription drugs from January 15, 2020 to March 15, 2020.
Please visit the HHSC Drug Cost Transparency website for a complete description of the program, instructions for submitting information, frequently asked questions, and contact information.